Skip to main content
. 2024 Jan 10;13:1210873. doi: 10.3389/fonc.2023.1210873

Figure 1.

Figure 1

(A) Brain T1-WI MRI showing a PR of the left frontal lesion but progression of other LM lesions to stereotactic radiation therapy (5*6 Gy) followed by paclitaxel-trastuzumab-pertuzumab. (B) Brain T1-WI MRI showing a diffuse PR of LM to intra-CSF MTX (3*15 mg) followed by intra-CSF trastuzumab (150 mg) with concomitant IV pertuzumab. (C) Brain T1-WI MRI showing a diffuse PR of LM to WBRT (10*3 Gy) with concomitant IV trastuzumab-emtansine. (D) Brain T1-WI MRI showing a diffuse PR of LM to IV trastuzumab-deruxtecan.